{"id":"best-supportive-care-bsc","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5278854","moleculeType":null,"molecularWeight":"1243.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BSC is not a drug but rather a clinical trial design element representing the standard of care baseline. It typically includes symptom management, palliative measures, and conventional treatments available to patients in the control group, allowing researchers to measure the incremental benefit of the investigational therapy against established clinical practice.","oneSentence":"Best Supportive Care (BSC) is a control or comparator arm in clinical trials that provides standard medical management and symptom relief without the investigational drug.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:02.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05664737","phase":"PHASE2","title":"A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-09","conditions":"Anemia","enrollment":189},{"nctId":"NCT04543591","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-10","conditions":"Thrombotic Microangiopathy","enrollment":148},{"nctId":"NCT03793361","phase":"PHASE2","title":"Phase II Study of Regorafenib as Maintenance Therapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2019-05-15","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":127},{"nctId":"NCT01900743","phase":"PHASE2","title":"Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2013-06-05","conditions":"Sarcoma","enrollment":219},{"nctId":"NCT07448493","phase":"","title":"Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Gastric Cancer, Esophageal Cancer, Brain Metastases","enrollment":230},{"nctId":"NCT07448662","phase":"","title":"Local Treatment Strategies for Brain Metastases of Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Colorectal Cancer, Brain Metastases, Adult","enrollment":700},{"nctId":"NCT06341712","phase":"PHASE2","title":"Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2024-11-22","conditions":"Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults","enrollment":10},{"nctId":"NCT05469737","phase":"PHASE2, PHASE3","title":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes","enrollment":230},{"nctId":"NCT02152631","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-10-03","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT07265674","phase":"PHASE3","title":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","status":"RECRUITING","sponsor":"J-Pharma Co., Ltd.","startDate":"2026-01","conditions":"Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)","enrollment":480},{"nctId":"NCT07327034","phase":"PHASE2","title":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","status":"RECRUITING","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2025-06-13","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":141},{"nctId":"NCT06824064","phase":"PHASE2","title":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2025-01-17","conditions":"Metastatic Colorectal Cancer, Advanced Colorectal Cancer","enrollment":150},{"nctId":"NCT07164443","phase":"PHASE3","title":"A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-02","conditions":"Metastatic Castration-resistant Prostate Neoplasms","enrollment":663},{"nctId":"NCT05024513","phase":"PHASE2","title":"Biliary Drainage Plus HAIC in Locally Advanced pCCA","status":"COMPLETED","sponsor":"Peking University","startDate":"2021-11-01","conditions":"Perihilar Cholangiocarcinoma","enrollment":127},{"nctId":"NCT07244367","phase":"NA","title":"Maintenance Venetoclax in AML Fit Patients","status":"RECRUITING","sponsor":"Sohag University","startDate":"2025-09-01","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":80},{"nctId":"NCT07225374","phase":"PHASE2","title":"Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-09-16","conditions":"Upper Tract Urothelial Carcinoma","enrollment":48},{"nctId":"NCT04644185","phase":"PHASE2, PHASE3","title":"The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19","status":"TERMINATED","sponsor":"Sinocelltech Ltd.","startDate":"2021-03-27","conditions":"Covid19","enrollment":102},{"nctId":"NCT04161885","phase":"PHASE3","title":"A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2020-02-26","conditions":"Acute Myeloid Leukemia (AML), Cancer","enrollment":465},{"nctId":"NCT03062358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-04-27","conditions":"Carcinoma, Hepatocellular","enrollment":453},{"nctId":"NCT02389244","phase":"PHASE2","title":"A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-09","conditions":"Ewing Sarcomas, Chondrosarcomas, Osteosarcomas","enrollment":163},{"nctId":"NCT04102020","phase":"PHASE3","title":"A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-03-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT02269280","phase":"PHASE2","title":"Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-13","conditions":"Leukemia","enrollment":185},{"nctId":"NCT05049044","phase":"","title":"Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francais De Pneumo-Cancerologie","startDate":"2020-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":413},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT04581473","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","status":"ACTIVE_NOT_RECRUITING","sponsor":"CARsgen Therapeutics Co., Ltd.","startDate":"2020-10-23","conditions":"Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":192},{"nctId":"NCT02577406","phase":"PHASE3","title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-30","conditions":"Leukemia, Myeloid, Isocitrate Dehydrogenase","enrollment":319},{"nctId":"NCT04322539","phase":"PHASE3","title":"A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2020-08-12","conditions":"Metastatic Colorectal Cancer, Metastatic Colon Cancer","enrollment":691},{"nctId":"NCT01566695","phase":"PHASE3","title":"The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-04-26","conditions":"Myelodysplastic Syndrome","enrollment":216},{"nctId":"NCT04713514","phase":"PHASE2","title":"OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2021-08-05","conditions":"Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer","enrollment":180},{"nctId":"NCT06665087","phase":"PHASE2","title":"CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11","conditions":"Colon Cancer, Rectal Cancer","enrollment":110},{"nctId":"NCT06652412","phase":"PHASE2","title":"CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11","conditions":"Colon Cancer, Rectal Cancer","enrollment":124},{"nctId":"NCT01607957","phase":"PHASE3","title":"Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2012-06-17","conditions":"Colorectal Cancer","enrollment":800},{"nctId":"NCT02500043","phase":"PHASE3","title":"Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2016-02-24","conditions":"Refractory Metastatic Gastric Cancer","enrollment":507},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT04193553","phase":"PHASE2","title":"Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2020-01-17","conditions":"Gastro Intestinal Stromal Tumour","enrollment":77},{"nctId":"NCT04655118","phase":"PHASE2","title":"Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis","status":"RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2020-10-22","conditions":"Myelofibrosis, Indolent Systemic Mastocytosis","enrollment":121},{"nctId":"NCT04806906","phase":"PHASE2","title":"Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florence","startDate":"2021-03-24","conditions":"MDS, CMML","enrollment":11},{"nctId":"NCT03721744","phase":"PHASE2, PHASE3","title":"A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"1Globe Health Institute LLC","startDate":"2018-10-25","conditions":"Metastatic Pancreatic Cancer","enrollment":336},{"nctId":"NCT02603432","phase":"PHASE3","title":"A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-04-25","conditions":"Urothelial Cancer","enrollment":700},{"nctId":"NCT03342404","phase":"PHASE2","title":"A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-02-05","conditions":"Thalassemia","enrollment":145},{"nctId":"NCT04333420","phase":"PHASE2, PHASE3","title":"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"InflaRx GmbH","startDate":"2020-03-31","conditions":"Severe COVID-19 Pneumonia","enrollment":399},{"nctId":"NCT04333108","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-07-01","conditions":"Indolent Systemic Mastocytosis","enrollment":140},{"nctId":"NCT02604433","phase":"PHASE3","title":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-05-02","conditions":"Erythrocyte Transfusion, Beta-Thalassemia","enrollment":336},{"nctId":"NCT01257139","phase":"PHASE3","title":"Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a \"Classical\" Strategy of Treatment Allocation, With an\"Optimized\" Strategy Allocating the Same Treatments","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2010-01","conditions":"Non Small-cell Lung Cancer","enrollment":490},{"nctId":"NCT04622865","phase":"PHASE2","title":"Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-06-01","conditions":"SARS-CoV 2, COVID-19, Coronavirus Disease 2019","enrollment":200},{"nctId":"NCT05449444","phase":"PHASE2","title":"Masitinib for the Treatment of Severe Mast Cell Activation Syndrome","status":"UNKNOWN","sponsor":"AB Science","startDate":"2022-07-01","conditions":"Mast Cell Activation Syndrome","enrollment":72},{"nctId":"NCT02088541","phase":"PHASE2","title":"Selinexor (KPT-330) in Older Patients With Relapsed AML","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2014-03","conditions":"Acute Myeloid Leukemia (AML)","enrollment":317},{"nctId":"NCT02435433","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-07-20","conditions":"Hepatocellular Carcinoma","enrollment":399},{"nctId":"NCT00113763","phase":"PHASE3","title":"Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-01-01","conditions":"Colorectal Cancer, Metastases","enrollment":463},{"nctId":"NCT02460419","phase":"PHASE3","title":"Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-04","conditions":"Nasopharyngeal Carcinoma","enrollment":104},{"nctId":"NCT03542461","phase":"PHASE3","title":"Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)","status":"UNKNOWN","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2017-09-25","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":125},{"nctId":"NCT02702401","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-26","conditions":"Hepatocellular Carcinoma","enrollment":413},{"nctId":"NCT02562443","phase":"PHASE3","title":"Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA","status":"TERMINATED","sponsor":"Traws Pharma, Inc.","startDate":"2015-12-02","conditions":"Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts","enrollment":372},{"nctId":"NCT02688647","phase":"PHASE2","title":"A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Kadmon Corporation, LLC","startDate":"2016-05-26","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":76},{"nctId":"NCT03042611","phase":"PHASE3","title":"A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer","status":"COMPLETED","sponsor":"Elevar Therapeutics","startDate":"2017-03-14","conditions":"Gastric Cancer, Gastric Adenocarcinoma","enrollment":460},{"nctId":"NCT02683941","phase":"PHASE3","title":"Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours","status":"TERMINATED","sponsor":"Ipsen","startDate":"2017-03-06","conditions":"Neuroendocrine Tumors in Lung","enrollment":77},{"nctId":"NCT02625610","phase":"PHASE3","title":"Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2015-12-24","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction","enrollment":499},{"nctId":"NCT04397718","phase":"PHASE2","title":"Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2020-07-06","conditions":"COVID-19","enrollment":96},{"nctId":"NCT04369469","phase":"PHASE3","title":"Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-05-10","conditions":"COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome","enrollment":202},{"nctId":"NCT03945084","phase":"PHASE2","title":"Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2019-08-27","conditions":"Urothelial Carcinoma","enrollment":58},{"nctId":"NCT05182944","phase":"PHASE2","title":"A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-01-15","conditions":"Esophageal Cancer","enrollment":130},{"nctId":"NCT01524783","phase":"PHASE3","title":"Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03-30","conditions":"Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors","enrollment":302},{"nctId":"NCT04475588","phase":"PHASE2","title":"Efficacy and Safety of Itolizumab in COVID-19 Complications","status":"COMPLETED","sponsor":"Biocon Limited","startDate":"2020-05-01","conditions":"Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19","enrollment":32},{"nctId":"NCT01100502","phase":"PHASE3","title":"A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2010-04-30","conditions":"Disease, Hodgkin","enrollment":329},{"nctId":"NCT03556956","phase":"PHASE2, PHASE3","title":"Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AB Science","startDate":"2015-07","conditions":"Colorectal Cancer Metastatic","enrollment":219},{"nctId":"NCT02625623","phase":"PHASE3","title":"Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2015-12-28","conditions":"Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line","enrollment":371},{"nctId":"NCT04183478","phase":"PHASE2, PHASE3","title":"The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-26","conditions":"Pancreatic Cancer","enrollment":600},{"nctId":"NCT04568330","phase":"NA","title":"Prevention of Hand-foot Skin Reaction","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2014-03-21","conditions":"Hepatocellular Carcinoma","enrollment":129},{"nctId":"NCT01774344","phase":"PHASE3","title":"Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-05-14","conditions":"Carcinoma, Hepatocellular","enrollment":573},{"nctId":"NCT02027428","phase":"PHASE3","title":"Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-02-11","conditions":"Squamous Cell Carcinoma, Non-Small-Cell Lung","enrollment":427},{"nctId":"NCT01241500","phase":"PHASE3","title":"Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts","status":"COMPLETED","sponsor":"Traws Pharma, Inc.","startDate":"2010-11","conditions":"Myelodysplastic Syndromes, MDS, RAEB","enrollment":299},{"nctId":"NCT02196688","phase":"PHASE2","title":"Study of Fruquintinib in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2014-04","conditions":"Colorectal Cancer","enrollment":71},{"nctId":"NCT02396641","phase":"NA","title":"PCRC Best Supportive Care (PCRC BSC)","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-03","conditions":"Feasibility of Best Supportive Care Delivery","enrollment":40},{"nctId":"NCT02314819","phase":"PHASE3","title":"A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2014-12","conditions":"Colorectal Cancer","enrollment":416},{"nctId":"NCT01741038","phase":"PHASE2, PHASE3","title":"AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Mirror Biologics, Inc.","startDate":"2017-12","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT00814073","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2008-12","conditions":"Indolent Systemic Mastocytosis","enrollment":135},{"nctId":"NCT00071799","phase":"PHASE3","title":"A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care","status":"COMPLETED","sponsor":"Celgene","startDate":"2003-11-01","conditions":"Myelodysplastic Syndromes","enrollment":358},{"nctId":"NCT02187042","phase":"","title":"Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-10-07","conditions":"Metastatic/Advanced Renal Cell Carcinoma","enrollment":70},{"nctId":"NCT00825955","phase":"PHASE3","title":"Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-02-17","conditions":"Liver Cancer","enrollment":587},{"nctId":"NCT00917384","phase":"PHASE3","title":"Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-08","conditions":"Gastric Cancer, Adenocarcinoma","enrollment":355},{"nctId":"NCT02008318","phase":"PHASE2, PHASE3","title":"A Study of Galunisertib in Participants With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-03","conditions":"Myelodysplastic Syndromes","enrollment":43},{"nctId":"NCT01287585","phase":"PHASE3","title":"Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy","status":"COMPLETED","sponsor":"Polaris Group","startDate":"2011-07","conditions":"Hepatocellular Carcinoma","enrollment":636},{"nctId":"NCT03516071","phase":"PHASE2","title":"A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC","status":"COMPLETED","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2017-05-17","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":90},{"nctId":"NCT01358734","phase":"PHASE2","title":"A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-04-27","conditions":"Acute Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":88},{"nctId":"NCT01248299","phase":"PHASE2","title":"Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2011-01","conditions":"Squamous Cell Carcinoma of Esophagus","enrollment":105},{"nctId":"NCT02176369","phase":"PHASE2","title":"Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-02","conditions":"Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":120},{"nctId":"NCT02083653","phase":"PHASE2","title":"Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Symphogen A/S","startDate":"2014-03-06","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT01210495","phase":"PHASE2","title":"Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12-06","conditions":"Hepatocellular Carcinoma","enrollment":224},{"nctId":"NCT02672527","phase":"PHASE3","title":"Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2015-01-22","conditions":"Soft Tissue Sarcoma","enrollment":103},{"nctId":"NCT01024036","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03-18","conditions":"Multicentric Castleman's Disease","enrollment":79},{"nctId":"NCT01529112","phase":"PHASE2","title":"A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-11","conditions":"Non-Small Cell Lung Cancer","enrollment":135},{"nctId":"NCT01074047","phase":"PHASE3","title":"Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Celgene","startDate":"2010-06-01","conditions":"Acute Myeloid Leukemia","enrollment":488},{"nctId":"NCT02149108","phase":"PHASE3","title":"Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-09-25","conditions":"Colorectal Neoplasms","enrollment":768},{"nctId":"NCT02060669","phase":"PHASE3","title":"Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2010-06-20","conditions":"Metastatic Colorectal Cancer","enrollment":10},{"nctId":"NCT01412957","phase":"PHASE3","title":"Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-11","conditions":"Metastatic Colorectal Cancer","enrollment":377},{"nctId":"NCT01015443","phase":"PHASE3","title":"Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-12","conditions":"Non-Small Cell Lung Cancer","enrollment":285},{"nctId":"NCT00508001","phase":"PHASE2","title":"Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-07","conditions":"Carcinoma, Hepatocellular","enrollment":67},{"nctId":"NCT01035229","phase":"PHASE3","title":"Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Carcinoma","enrollment":546},{"nctId":"NCT00656136","phase":"PHASE3","title":"BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":585},{"nctId":"NCT00259064","phase":"PHASE2, PHASE3","title":"Iressa v BSC (Best Supportive Care) in First Line NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"NSCLC","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Best Supportive Care (BSC)","genericName":"Best Supportive Care (BSC)","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}